Joseph Rosenblatt
Endocrinology, Diabetes & Metabolism · New Britain, CTNPI 1922094838
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $203,203 of the $234,843 with a category attached, or 86.5%. Lilly USA, LLC accounts for 67.4% of it on its own, with 33 other manufacturers making up the rest. Reporting peaked in 2019 at $127,264 and has fallen 99.9% since, to $121 in 2025. Among endocrinology, diabetes & metabolism clinicians in CT with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 667 payments — averaging $352.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$158K
- Abbott$24K
- Novo Nordisk$22K
- Sanofi-aventis U.S. LLC$9K
- Amarin Pharma, Inc.$8K
- Johnson & Johnson$7K
- plus $7K from 28 others
What the payments were for
- Consulting fees$7,1603%
- Speaking & faculty fees$203,20387%
- Travel & lodging$12,4045%
- Food & beverage$12,0385%
- Education$380%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 337 | $158,319 |
| Abbott | 54 | $23,681 |
| Novo Nordisk | 80 | $21,969 |
| Sanofi-aventis U.S. LLC | 20 | $9,315 |
| Amarin Pharma, Inc. | 36 | $8,373 |
| Johnson & Johnson | 29 | $6,639 |
| Dexcom, Inc. | 11 | $2,639 |
| Amgen | 12 | $676 |
| AstraZeneca | 11 | $666 |
| Boehringer Ingelheim | 12 | $328 |
| Esperion Therapeutics, Inc. | 2 | $250 |
| AbbVie(2 entities) | 8 | $244 |
| Bayer | 2 | $224 |
| Tandem Diabetes Care, Inc. | 4 | $221 |
| Pfizer | 12 | $148 |
| Smith+Nephew | 1 | $145 |
| Corcept Therapeutics | 2 | $136 |
| Senseonics, Incorporated | 1 | $130 |
| GSK | 7 | $121 |
| Ascendis Pharma Endocrinology Inc | 1 | $121 |
| Radius Health, Inc. | 1 | $106 |
| Astellas Pharma US Inc | 5 | $62 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 4 | $58 |
| Merck | 4 | $57 |
| Orthofix Medical, Inc. | 1 | $51 |
| Sanofi Pasteur Inc. | 2 | $36 |
| Shire North American Group Inc | 1 | $19 |
| Medtronic | 1 | $17 |
| Otsuka America Pharmaceutical, Inc. | 1 | $17 |
| Xeris Pharmaceuticals, Inc. | 1 | $17 |
| Scilex Pharmaceuticals Inc. | 1 | $16 |
| Aytu Biopharma, Inc. | 1 | $15 |
| Bausch Health US, LLC | 1 | $14 |
| Genentech USA, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TRULICITY$131,681
- BAQSIMI$19,988
- FreeStyle Libre Pro$14,424
- Ozempic$9,540
- Vascepa$7,905
- SOLIQUA 100/33$7,662
- INVOKANA$6,187
- Tresiba$5,933
- FreeStyle Libre$5,423
- FreeStyle Libre 2$3,234
- Saxenda$2,040
- DEXCOM CGM$2,006
- Victoza$1,870
- TOUJEO$1,418
- DEXCOM G6 TRANSMITTER$525
- FARXIGA$476
- NEXLIZET$250
- NEXLETOL$250
- Repatha$238
- EVENITY$226
How this compares
$234,843 in reported general payments places this provider in the 95th percentile of 177 endocrinology, diabetes & metabolism providers in Connecticut.
See all endocrinology, diabetes & metabolism providers in Connecticut →
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Cinacalcet Hcl | 12 | $186 |
Paid to pharmacies, not to this prescriber.
Other endocrinology, diabetes & metabolism in New Britain
- Manmeet KaurNew Britain$44K
- Ela BanerjeeNew Britain$8K
- Egils BogdanovicsTorrington$608K
- Ania JastreboffNew Haven$536K
- Robert ObersteinHartford$516K
- Fadi Al-KhayerStorrs$489K
- Silvio InzucchiNew Haven$461K
- Philip GoldbergNew Haven$324K
- Kevan HeroldNew Haven$261K
- David DomenichiniBloomfield$220K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.